Clinical Trial

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
Protocol Amendment History 2 changes
notable Trial sites expanded: 65 -> 74 locations 2026-06-27
notable Trial sites expanded: 52 -> 65 locations 2026-05-15
Trial Details
NCT Number NCT07094516
Lead Sponsor Novartis Pharmaceuticals
Conditions Alzheimer's Disease
Enrollment 407 participants
Start Date 2025-08-07
Primary Completion 2028-09-14 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-26